USANA Health Sciences (NYSE:USNA) Downgraded to "Hold" Rating by Zacks Research

Key Points

• USANA Health Sciences was downgraded from a "strong-buy" to a "hold" rating by Zacks Research.
• The company's latest earnings report showed an EPS of $0.74, exceeding analysts' expectations of $0.54, with revenue of $235.85 million.
• Insider trading activity includes sales by top executives, with David Mulham selling 3,515 shares, indicating a potential decrease in confidence among company leadership.

USANA Health Sciences (NYSE:USNA - Get Free Report) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a report issued on Monday,Zacks.com reports.

USANA Health Sciences Price Performance

Shares of NYSE:USNA opened at $28.97 on Monday. The business has a 50-day moving average of $30.73 and a two-hundred day moving average of $29.49. The firm has a market capitalization of $529.35 million, a PE ratio of 16.10, a P/E/G ratio of 0.94 and a beta of 0.64. USANA Health Sciences has a 12 month low of $23.10 and a 12 month high of $41.83.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The company reported $0.74 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.54 by $0.20. The business had revenue of $235.85 million during the quarter, compared to analysts' expectations of $225.20 million. USANA Health Sciences had a return on equity of 9.48% and a net margin of 3.79%. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. As a group, research analysts anticipate that USANA Health Sciences will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider David Mulham Mulham sold 3,515 shares of USANA Health Sciences stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total transaction of $106,363.90. Following the transaction, the insider owned 9,260 shares in the company, valued at approximately $280,207.60. The trade was a 27.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gilbert A. Fuller sold 1,058 shares of the company's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $29.10, for a total transaction of $30,787.80. The disclosure for this sale can be found here. Company insiders own 0.63% of the company's stock.

Institutional Investors Weigh In On USANA Health Sciences

Several hedge funds have recently modified their holdings of the stock. US Bancorp DE lifted its position in USANA Health Sciences by 13.1% during the 1st quarter. US Bancorp DE now owns 4,611 shares of the company's stock worth $124,000 after acquiring an additional 535 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in shares of USANA Health Sciences by 7.1% during the first quarter. Exchange Traded Concepts LLC now owns 9,184 shares of the company's stock worth $248,000 after purchasing an additional 606 shares in the last quarter. Creative Planning lifted its position in shares of USANA Health Sciences by 3.2% during the second quarter. Creative Planning now owns 20,051 shares of the company's stock worth $612,000 after purchasing an additional 613 shares in the last quarter. Quantbot Technologies LP boosted its stake in shares of USANA Health Sciences by 19.5% in the second quarter. Quantbot Technologies LP now owns 3,957 shares of the company's stock valued at $121,000 after purchasing an additional 646 shares during the period. Finally, PNC Financial Services Group Inc. grew its holdings in USANA Health Sciences by 339.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 998 shares of the company's stock valued at $27,000 after purchasing an additional 771 shares in the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.